

1 **Early Side Effects after Administration of the 1st Dose of Oxford-AstraZeneca Vaccine**

2 **Short title: Side Effects AstraZeneca**

3

4 Pramod Singh^{1*}, Abdul Rafae Faisal¹, M. Hassaan Shah², Ahmad Saeed¹, Hadia Younas³,
5 Usamah Saeed Butt⁴, Sudip Pudasaini⁵, Abdul Rafay Pasha⁶, Umair Rehman¹

6

7 ¹ Department of Surgery, Punjab Medical College, Faisalabad, Punjab, Pakistan

8 ² Department of Medicine, Qazi Hussain Ahmad Medical Complex, Nowshera, KPK,

9 Pakistan

10 ³ Department of Medicine, Services Institute of Medical Sciences, Lahore, Punjab, Pakistan

11 ⁴ Department of Medicine, King Edward Medical University, Lahore, Pakistan

12 ⁵ Department of Medicine, Nepal Medical College, Kathmandu, Nepal

13 ⁶ Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan

14

15 *Corresponding author

16 E-mail: singhutd66@gmail.com

17

18 **Abstract**

19 Vaccines have played a central role in minimizing new infections, the rate of hospitalizations,
20 and the overall burden on the health sector. Fear of side-effects is the biggest and commonest
21 reason for avoiding getting vaccinated. It is, therefore, essential to maintain the clarity and
22 consistency of message, to support and encourage people to get vaccinated. This study aims
23 to contribute in that regard, by registering and quantifying the early side-effects of the
24 Oxford-AstraZeneca COVID-19 vaccine in Pakistan. This study employs a non-random
25 cross-sectional design. Data collected from 477 participants using a structured questionnaire
26 was used to investigate the relationship between socio-demographic characteristics and side
27 effect profiles of the participants. Binomial Logistic Regression was used to analyze the data.
28 Odds Ratio (OR) gives the likelihood of having a side effect versus the reference group.
29 Significance level (α) for the probability value (p-value) is set at 0.05. Fever (30.19%) was
30 the most commonly experienced side effect, followed closely by fatigue (22.01%). 71.11% of
31 those with fever experienced low grade fever (99-100F) while 62.69% of body aches
32 experienced were moderate in intensity (Grades 4-6). In general, younger people are
33 significantly more likely ($p=0.023$) to experience side effects ($OR^{-1} = 1.023$: interpreted as
34 1.023 times increase per unit decrease in age). Similarly, they are more likely ($p= 0.029$) to
35 have a headache ($OR^{-1} =1.039$). Also, they are more likely ($p= 0.007$) to have a body ache
36 ($OR^{-1} =1.038$). The Oxford-AstraZeneca COVID-19 vaccine side-effects seem to be more
37 prevalent among younger age groups, which points to increased vaccine safety among older
38 individuals that are usually more susceptible to severe COVID-19 infection. In addition, we
39 found a substantially reduced number of side-effects, as compared to the clinical trials, which
40 is an encouraging indicator for vaccine safety.

41 **Introduction**

42 Since the COVID-19 pandemic started in early 2020, the world has undergone drastic and
43 disruptive changes. The wave upon wave of new infections, constantly having to follow
44 restrictions and fears of the deadly disease has left enduring scars on the public psyche [1].
45 Not only this, but the pandemic has led to trillions of dollars of loss to the world economy
46 [2].

47 For this pandemic to end, vaccines have played a central role in minimizing new infections,
48 the rate of hospitalizations and the overall burden on the health sector. A large percentage of
49 the world's population has to be vaccinated in a short period of time to achieve the herd
50 immunity required to stop the propagation of the Coronavirus [3].

51 These vaccines have varying mechanisms of actions. Some are mRNA vaccines, like Pfizer-
52 BioNTech and Moderna COVID-19 vaccines, while others, like the Janssen shot, are non-
53 replicating viral vector vaccines. Moreover, the Oxford-AstraZeneca vaccine is an
54 Adenovirus vaccine and Sputnik V is a recombinant Adenovirus vaccine. Many others are
55 inactivated vaccines like Sinopharm and Sinovac vaccines [4, 5].

56 Side effects have been the cause of concern for many and have led to delay in getting
57 vaccinated. This delay in vaccine acceptance, vaccine hesitancy, is turning out to be an
58 emerging public health problem. [6, 7] According to multiple studies, fear of side-effects is
59 the biggest and commonest reason for avoiding getting vaccinated [8, 9]. It is, therefore,
60 essential to maintain the clarity and consistency of message, to support and encourage people
61 to get vaccinated.

62 Pakistan started its vaccination campaign with Sinopharm, Sinovac, CanSino and Sputnik V
63 [10]. This effort received public backlash from some quarters. Keeping in mind the dire need
64 of the rapid vaccination of the masses, it is important to maintain the public's trust, which can
65 only be based on adequate statistical data regarding the safety of the vaccine. This study aims
66 to contribute in that regard, by registering and quantifying the early side-effects of the
67 Oxford-AstraZeneca COVID-19 vaccine in Pakistan.

68 **Materials and Methods**

69 The study was conducted in July 2021. All individuals presenting at the vaccination site that
70 were within government-approved age groups (at the time of data collection, 40 years and
71 above) were considered for the study.

72 Individuals with acute febrile illness (last 72 hours), history of COVID-19 infection (positive
73 PCR), prior COVID-19 vaccination., history of foreign travel during the past 3 months,
74 receiving any investigational drug for COVID-19 (including for prophylaxis) during the last
75 30 days, receiving systemic immunoglobulins, monoclonal antibodies and/or convalescent
76 serum during the past 4 months, significant or severe co-morbidities [Diabetes mellitus,
77 hypertension, chronic pulmonary disease, asthma, active smoker or vapers (during the past
78 year), BMI> 30 Kg/m², history of anaphylaxis or urticaria or other adverse effects related to
79 vaccine or its components, severe or uncontrolled heart disease, cancer and any other severe
80 disease, bleeding disorder, known or suspected immunodeficient status [HIV,
81 immunosuppressive drugs (cytotoxins and steroids) and asplenia], blood donation during the
82 last 28 days, known or suspected alcohol or drug dependency, pregnancy or breastfeeding,
83 participating in any research study during the past 28 days were excluded from the study.

84 This study employs a non-random cross-sectional design. Data collected from 477
85 participants using a structured questionnaire was used to investigate the relationship between
86 socio-demographic characteristics and side effect profiles of the participants. Only those
87 participants that met the inclusion criteria for this study were selected for follow up. The
88 participants were followed on Day 1, 3, and 7 to gather data regarding side-effects. Data was
89 analyzed descriptively and inferentially by IBM SPSS 24. Binomial Logistic Regression was
90 used to analyze the data. For missing data regarding Educational status, data was imputed
91 using mice package in R. Odds Ratio (OR) gives the likelihood of having a side effect versus
92 the reference group. Significance level (α) for the probability value (p-value) is set at 0.05.

93 **Results**

94 477 individuals participated in this study. Of them, 51.15% of the respondents belonged to
 95 the 40-49 age group, followed by the 50-59 age group which had 31.24% participants.
 96 44.89% had primary education or below. A vast majority, 72.54%, were male. Fever
 97 (30.19%) was the most commonly experienced side effect, followed closely by fatigue
 98 (22.01%). 71.11% of those with fever experienced low grade fever (99-100F) while 62.69%
 99 of body aches experienced were moderate in intensity (Grades 4-6) [Table 1]. In general,
 100 younger people are significantly more likely ($p=0.023$) to experience side effects ($OR^{-1} =$
 101 1.023 : interpreted as 1.023 times increase per unit decrease in age). Similarly, they are more
 102 likely ($p= 0.029$) to have a headache ($OR^{-1} =1.039$). Also, they are more likely ($p= 0.007$) to
 103 have a body ache ($OR^{-1} =1.038$). In general, higher educational status reported a higher
 104 frequency of side effects ($p< 0.05$) [Table 2].

105 Table 1. Frequency of side effects.

Side effects	Frequency	Percentage
Headache	21	4.4
Flu-like illness	0	0
Pain, swelling, rash, bleeding or redness at the site of injection	56	11.74
Fatigue	18	3.77
Anaphylaxis reaction	1	0.21
Fever	144	30.19
Low Grade [99F -100F]	64	71.11
Moderate [100.1F -103 F]	21	23.33
High grade [103.1 F-106 F]	5	5.56
Undocumented	54	-
Body ache	105	22.01
Grade (1-3)	8	11.94
Grade (4-6)	42	62.69
Grade (7-9)	17	25.37
Undocumented	38	-

106 Table 2. Binary Logistic Regression.

Side effect	Variables	Reference group	Log odds	p-value	Ordinal Regression(OR)
Headache	Age		-0.077	0.029*	0.926
	Male	Female	0.521	0.339	1.685
	Matric or Below	Primary or below	0.269	0.658	1.31
	Intermediate or below	Primary or below	-16.268	0.989	0
	Bachelors and above	Primary or below	1.378	0.015*	3.968
	Urban	Rural	-0.897	0.210	0.408
Injection site reaction	Age		-0.017	0.304	0.983

	Male	Female	0.081	0.803	1.085
	Matric or Below	Primary or below	0.083	0.829	1.085
	Intermediate or below	Primary or below	0.526	0.21	1.693
	Bachelors and above	Primary or below	0.459	0.272	1.583
	Urban	Rural	-0.440	0.327	0.644
Fatigue	Age		0.014	0.583	1.014
	Male	Female	-0.845	0.091	0.43
	Matric or Below	Primary or below	1.422	0.030*	4.149
	Intermediate or below	Primary or below	-0.076	0.947	0.927
	Bachelors and above	Primary or below	1.620	0.022*	5.058
	Urban	Rural	-0.070	0.932	1.81x10 ⁸
Anaphylaxis	Age		-0.085	0.587	0.918
	Male	Female	-19.4	0.999	0
	Matric or below	Primary or below	-18.8	0.999	0
	Intermediate or below	Primary or below	-19.1	0.999	0
	Bachelors and above	Primary or below	-19.8	0.999	0
	Urban	Rural	19	0.999	1.81x10 ⁸
Fever	Age		-0.015	0.182	0.984
	Male	Female	0.180	0.442	1.198
	Matric or Below	Primary or below	-0.410	0.149	0.663
	Intermediate or below	Primary or below	0.480	0.107	1.616
	Bachelors and above	Primary or below	0.719	0.0128*	2.053
	Urban	Rural	0.705	0.074	2.025
Body ache	Age		-0.037	0.007*	0.963
	Male	Female	-0.194	0.433	0.823
	Matric or Below	Primary or below	0.394	0.168	1.483
	Intermediate or below	Primary or below		0.966	1.015
	Bachelors and above	Primary or below	0.571	0.075	1.771
	Urban	Rural	-0.287	0.430	0.75
Any side effect	Age		-0.023	0.023*	0.977
	Male	Female	0.189	0.367	1.209
	Matric or Below	Primary or below	0.169	0.475	1.184

Intermediate or below	Primary or below	0.389	0.176	1.477
Bachelors and above	Primary or below	0.371	0.185	1.451
Urban	Rural	-0.100	0.733	0.904

107 *probability value (p-value) <0.05

108 Discussion

109 In this study, we attempted to confirm the presence and measure the frequency of occurrence
110 of AstraZeneca vaccine's early adverse effects in Pakistan. These included headache, body
111 aches, fatigue, fever, injection site reaction, flu-like illness and anaphylaxis. Except for the
112 flu-like illness and anaphylaxis, for all COVID-19 vaccines, these early side effects are,
113 generally speaking, the commonest early COVID-19 vaccine side effects [11]. 49.47% of the
114 respondents in our study had, at least, one of these symptoms.

115 The side-effects were categorized as local and systemic. Local effects refer to injection site
116 reactions which include pain, swelling, rash, redness or bleeding at the site of vaccination.
117 They were present only in 11.74% of the study population which is in marked contrast to
118 phase 2/3 trials, that showed a considerably higher occurrence across all age groups (88% in
119 the 18–55 years group, 73% in the 56–69 years group, and 61% in 70 years and older group),
120 and phase 1/ 2 trials, conducted in UK, at 67% [12, 13]. It is, however, much closer to a
121 regional study conducted in Bangladesh (35.5%) [14] Most of the local adverse effects
122 occurred on the first and second post-vaccination day, while a few were recorded on the third
123 day. None were reported in the following days. This is in line with the results of the clinical
124 trials [12].

125 On the other hand, the systemic adverse effects solicited included headache, fever, flu-like
126 illness, body aches, fatigue and anaphylaxis. At least one systemic effect was reported by
127 42.76% of the study participants, which is considerably lower than the results of the phase 2/
128 3 trials (86% in the 18–55 years group, 77% in the 56–69 years group, and 65% in the 70
129 years and older group) [12].

130 Fever, at 30.19%, was present in a greater number of individuals than any other side effect.
131 The phase 2/ 3 trials show a similar result with 24% incidence in the 18-55 age and no reports
132 of fever in the 55 or above age group. They are also similar to the results of the Bangladeshi
133 study (20%) mentioned above [12, 14]. Another study conducted on those 50 years old and
134 above reported a lower incidence of 10% [15].

135 Of those that reported fever, nearly three quarters (71.11%) had only a mild case of it.
136 Another 23.33% reported moderate fever and very few individuals reported incidence of high
137 grade fever. This is in accordance with phase 2/3 trials [12].

138 Body aches were reported by 22.01% of the participants. This figure is much lower than the
139 phase 1/2 trials (60%) and much closer to a regional study (16.4%) [13, 14]. Body aches were
140 categorized using a numerical scale from 1 to 10. Over half (62.69%) of the people with body

141 aches reported moderate (4 to 6) while a significant number (25.37%) of them also had severe
142 body aches (7 to 10). This agrees with prior reports of mostly moderate systemic side-effects.
143 [16]

144 Headache was present in a mere 4.40% of the respondents. This is, again, in concurrence with
145 the Bangladeshi study (6.9%) rather than the clinical trial results (68%). Fatigue was reported
146 by 3.77% of the participants, a result similar to the Bangladeshi study, and there was not a
147 single case of flu-like illness [14].

148 One case of anaphylactic reaction was also registered, which is in accordance with its rare
149 occurrence in similar studies [12, 16]. This hypersensitivity is probably due to polysorbate 80
150 which is present in adenoviral vector vaccines. These excipients serve to increase absorption,
151 improve solubility, and enhance stability of the whole product [17, 18].

152 The development and progress of side-effects were assessed through multiple follow-ups
153 during the 7-day time period. All of them appeared on Day 1 and most disappeared by Day 4.
154 A majority of symptoms were present on Day 2 (frequency = 316), followed by Day 1 (219)
155 and Day 3 (122). There was always a dramatic fall off, by Day 4 (13). Rarely did a symptom
156 persist till Day 5 (2). The mean duration of symptoms was (1.9 ± 0.7), which is very similar to
157 reported in a study in Bangladesh (1.9 ± 1.3 day).

158 The inferential analysis yielded a significant inverse relationship between age and headache
159 and age and body aches. Generally, younger individuals were at a greater risk of exhibiting
160 adverse effects than their older counterparts. This is in accordance with multiple studies [12,
161 16, 19]. An explanation of this phenomenon lies in the fact that younger individuals form
162 stronger immune responses which naturally lead to a greater number of such side-effects [20].
163 That may be a reason for the reduced frequencies of side-effects in this study, as the average
164 age was 51.28 years (AstraZeneca vaccine was available only for those who were 40 years
165 old or above, at the time of data collection). Nevertheless, it cannot be the sole cause behind
166 considerable differences in results. This is supported by the fact that some studies have
167 shown that there are far fewer real-world side-effects of these vaccines [14, 19]. Natural
168 variations among different populations also exist and must have a part to play in it.

169 No significant associations were found for sex or residence. This is in contrast to past studies
170 that found an association between sex and the occurrence of side-effects [17, 19].

171 Studies on vaccine side-effects cite past COVID-19 infection and co-morbidities as among
172 the risk factors for the emergence of post-vaccination adverse effects (although one study
173 shows an opposite relationship for the latter) [14, 21].

174 **Conclusion**

175 The Oxford-AstraZeneca COVID-19 vaccine side-effects seem to be more prevalent among
176 younger age groups, which points to increased vaccine safety among older individuals that
177 are usually more susceptible to severe COVID-19 infection. They are not associated with sex
178 and residence. However, education is positively associated with them, which might indicate a
179 nocebo effect among the educated resulting from higher awareness and knowledge about
180 side-effects. Finally, we found a substantially reduced number of side-effects, as compared to
181 the clinical trials, which is an encouraging indicator for vaccine safety.

182 We enacted stringent and expansive exclusion criteria to eliminate nearly all chronic illnesses
183 and co-morbidities that may influence the results. Similarly, we did not include individuals
184 with past COVID-19 infection (positive PCR test in the past). This was done in the interest of
185 reducing all possible risk factors, which may inflate the figures, to a minimum and to increase
186 the confidence in the results generated. While it is a fact that increasing age is inversely
187 correlated with the development of said side-effects, as mentioned above, the responsibility
188 for the considerably lower frequency of their occurrence cannot be laid solely at the feet of
189 higher median age, in this study. Further independent, prospective studies are required to
190 detect all the factors at play.

191 **Acknowledgements**

192 None.

193 **Limitations**

194 As the follow-ups were done via phone calls rather than in-person (owing to pandemic-
195 induced restrictions), the data is subject to reporting and recall bias. At any rate, 3 equally
196 spaced follow-ups, which allowed for cross and secondary questioning, kept such issues to a
197 minimum. No serological testing was included, which may give an idea about the unknown
198 risk factors.

199 **References**

- 200 1. Khan KS, Mamun MA, Griffiths MD, Ullah I. The mental health impact of the
201 COVID-19 pandemic across different cohorts. *International Journal of Mental Health*
202 *and Addiction*. 2020;20(1):380–6.
- 203 2. Szmigiera M. Impact of the coronavirus pandemic on the global economy - Statistics
204 & Facts [Internet]. Statista. 2021 [cited 2022Jun29]. Available from:
205 [https://www.statista.com/topics/6139/covid-19-impact-on-the-global-](https://www.statista.com/topics/6139/covid-19-impact-on-the-global-economy/#dossierSummary)
206 [economy/#dossierSummary](https://www.statista.com/topics/6139/covid-19-impact-on-the-global-economy/#dossierSummary)
- 207 3. Randolph HE, Barreiro LB. Herd immunity: Understanding covid-19. *Immunity*.
208 2020;52(5):737–41.
- 209 4. Zimmer C, Corum J, Wee S-lee, Kristoffersen M. Coronavirus vaccine tracker
210 [Internet]. *The New York Times*. The New York Times; 2020 [cited 2022Jun29].
211 Available from: [https://www.nytimes.com/interactive/2020/science/coronavirus-](https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html)
212 [vaccine-tracker.html](https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html)

- 213 5. Craven J. Covid-19 Vaccine tracker [Internet]. Regulatory Affairs Professionals
214 Society (RAPS). [cited 2022Jun29]. Available from: [https://www.raps.org/news-and-](https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker)
215 [articles/news-articles/2020/3/covid-19-vaccine-tracker](https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker)
- 216 6. Harrison EA, Wu JW. Vaccine confidence in the time of COVID-19. *European*
217 *journal of epidemiology*. 2020 Apr;35(4):325-30.
- 218 7. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, Srouji S, Sela
219 E. Vaccine hesitancy: the next challenge in the fight against COVID-19. *European*
220 *journal of epidemiology*. 2020 Aug;35(8):775-9.
- 221 8. Luyten J, Bruyneel L, van Hoek AJ. Assessing vaccine hesitancy in the UK
222 population using a generalized vaccine hesitancy survey instrument. *Vaccine*. 2019
223 Apr 24;37(18):2494-501.
- 224 9. Szmyd B, Karuga FF, Bartoszek A, Staniecka K, Siwecka N, Bartoszek A, Błaszczyk
225 M, Radek M. Attitude and behaviors towards SARS-CoV-2 vaccination among
226 healthcare workers: A cross-sectional study from Poland. *Vaccines*. 2021 Mar
227 4;9(3):218.
- 228 10. Ministry of National Health Services Regulations and Coordination. Vaccine
229 Statistics [Internet]. COVID. [cited 2022Jun29]. Available from:
230 <https://covid.gov.pk/vaccine-details>
- 231 11. World Health Organization. Statement for healthcare professionals: How COVID-19
232 vaccines are regulated for safety and effectiveness (revised March 2022) [Internet].
233 World Health Organization. [cited 2022Jun29]. Available from:
234 [https://www.who.int/news/item/11-06-2021-statement-for-healthcare-professionals-](https://www.who.int/news/item/11-06-2021-statement-for-healthcare-professionals-how-covid-19-vaccines-are-regulated-for-safety-and-effectiveness)
235 [how-covid-19-vaccines-are-regulated-for-safety-and-effectiveness](https://www.who.int/news/item/11-06-2021-statement-for-healthcare-professionals-how-covid-19-vaccines-are-regulated-for-safety-and-effectiveness)
- 236 12. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR,
237 Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S. Safety and
238 immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost
239 regimen in young and old adults (COV002): a single-blind, randomised, controlled,
240 phase 2/3 trial. *The Lancet*. 2020 Dec 19;396(10267):1979-93.
- 241 13. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S,
242 Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C. Safety and immunogenicity
243 of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a
244 phase 1/2, single-blind, randomised controlled trial. *The Lancet*. 2020 Aug
245 15;396(10249):467-78.
- 246 14. Khalil M, Mahbub-Uz-Zaman K, Hossain AS, Ahmed F, Chowdhury M, Karim F,
247 Khan ST, Miah M, Alam S, Khaleque N, Kibria M. Adverse events following
248 COVISHIELD vaccination among adult population in Bangladesh. *SN*
249 *Comprehensive Clinical Medicine*. 2021 Nov;3(11):2207-13.
- 250 15. Iacobucci G. COVID-19: fever, chills, and aches more common when AstraZeneca
251 and Pfizer vaccines are mixed, early data show. *BMJ: British Medical Journal*
252 (Online). 2021 May 12;373.
- 253 16. Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of
254 COVID19 vaccines among Iraqi population; a comparison between the three available
255 vaccines in Iraq; a retrospective cross-sectional study. *Diabetes & Metabolic*
256 *Syndrome: Clinical Research & Reviews*. 2021 Sep 1;15(5):102207.
- 257 17. Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of
258 COVID19 vaccines among Iraqi population; a comparison between the three available
259 vaccines in Iraq; a retrospective cross-sectional study. *Diabetes & Metabolic*
260 *Syndrome: Clinical Research & Reviews*. 2021 Sep 1;15(5):102207.
- 261 18. Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A,
262 Assimakopoulos SF, Gogos C, Kouni SN, Kounis GN, Calogiuri G. Allergic reactions

- 263 to current available COVID-19 vaccinations: pathophysiology, causality, and
264 therapeutic considerations. *Vaccines*. 2021 Mar 5;9(3):221.
- 265 19. Kadyrova I, Yegorov S, Negmetzhanov B, Kolesnikova Y, Kolesnichenko S,
266 Korshukov I, Baiken Y, Matkarimov B, Miller MS, Hortelano GH, Babenko D.
267 Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective
268 cohort study. *medRxiv*. 2022 Jan 1.
- 269 20. 10- Lawton G. You're only as young as your immune system. *New Scientist*. 2020
270 Mar 28;245(3275):44-8.
- 271 21. Riad A, Pokorná A, Mekhemar M, Conrad J, Klugarová J, Koščík M, Klugar M, Attia
272 S. Safety of ChAdOx1 nCoV-19 vaccine: independent evidence from two EU states.
273 *Vaccines*. 2021 Jun 18;9(6):673.